Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Corcept's Phase III trial of relacorilant with nab-paclitaxel has met its primary endpoint, demonstrating an improvement in ...

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

Experts discuss the 5-year efficacy and safety outcomes of polatuzumab in diffuse large B-cell lymphoma (DLBCL), highlighting ...

EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...